{"organizations": [], "uuid": "88afba30b5ffec4dc1cf71f6eaba6ad09601eb4e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-shire-announces-fda-acceptance-of/brief-shire-announces-fda-acceptance-of-sbla-for-cinryze-for-pediatric-hereditary-angioedema-use-idUSASB0C5XK", "country": "US", "domain_rank": 408, "title": "Shire Announces FDA Acceptance Of sBLA For Cinryze For Pediatric Hereditary Angioedema Use", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.168, "site_type": "news", "published": "2018-02-15T20:13:00.000+02:00", "replies_count": 0, "uuid": "88afba30b5ffec4dc1cf71f6eaba6ad09601eb4e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shire-announces-fda-acceptance-of/brief-shire-announces-fda-acceptance-of-sbla-for-cinryze-for-pediatric-hereditary-angioedema-use-idUSASB0C5XK", "ord_in_thread": 0, "title": "Shire Announces FDA Acceptance Of sBLA For Cinryze For Pediatric Hereditary Angioedema Use", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "shire plc", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "shire announces fda", "sentiment": "negative"}, {"name": "pdufa", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "  Updated 5 minutes ago BRIEF-Shire Announces FDA Acceptance Of sBLA For Cinryze For Pediatric Hereditary Angioedema Use Reuters Staff Feb 15 (Reuters) - Shire Plc: * SHIRE ANNOUNCES FDA ACCEPTANCE OF SBLA FOR CINRYZEÂ® FOR PEDIATRIC HEREDITARY ANGIOEDEMA USE * SHIRE PLC - FILING HAS RECEIVED PRIORITY REVIEW DESIGNATION FROM FDA * SHIRE PLC - FDA EXPECTED TO PROVIDE DECISION ON EXPANDED INDICATION OF CINRYZE BY JUNE 20, 2018, BASED ON PDUFA V ACTION DAT  ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-15T20:13:00.000+02:00", "crawled": "2018-02-15T14:21:46.003+02:00", "highlightTitle": ""}